In The News

November 9, 2020
President-elect Joe Biden and the head of the U.S. Food and Drug Administration's vaccines unit each said they were gearing up for the next phase of the nation's response to the COVID-19 pandemic, as…
November 9, 2020
The US Food and Drug Administration’s (FDA’s) Peter Marks, MD, directs the agency’s Center for Biologics Evaluation and Research (CBER). In a wide-ranging 6 November discussion with the president and…
November 5, 2020
The global “COVID-19 diagnostics market size” is projected to reach USD 11.40 billion by 2027, exhibiting a CAGR of 7.9% during the forecast period. Uncontrolled spread of the coronavirus worldwide…
October 27, 2020
Summary Background The Lung Cancer Master Protocol (Lung-MAP; S1400) is a completed biomarker-driven master protocol designed to address an unmet need for better therapies for squamous non-small-…
October 27, 2020
In the last issue issue of Targeted Therapies in Oncology, Marcus Neubauer, MD, chief medical officer for The US Oncology Network, and I kicked off a 2-part series exploring the implications of the…
October 26, 2020
Key Prominent Players Covered in the COVID-19 Diagnostics Market Research Report Are PerkinElmer Inc., Quest Diagnostics Incorporated, Quidel Corporation, Siemens Healthcare GmbH, Abbott, Thermo…
October 20, 2020
Though clinical research, in general, has been challenged during the COVID-19 pandemic, oncology trials “have several unique considerations due to disease severity, regimen complexity, and acute care…
October 20, 2020
In the 1970s, cancer survival was poor for young children and older adults in the United States, as shown by data published in the Journal of the National Cancer Institute. Great progress has been…
October 20, 2020
NEW YORK (Reuters Health) - New findings debunk the conventional wisdom that Black cancer patients are less likely to agree to participate in clinical trials. Overall, 55% of patients offered trial…
October 19, 2020
On a daily basis, the U.S. Food and Drug Administration is responsible for making highly complex and consequential regulatory decisions. To meet this responsibility, the FDA must have a modern…